Navigation Links
Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
Date:3/27/2008

CHICAGO, IL MARCH 27, 2008 The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.

The analysiswhich includes approximately 180,000 patients from 52 studieswas performed by a team of researchers led by Ajay J. Kirtane, MD, Assistant Professor of Clinical Medicine and an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center, and Gregg W. Stone, MD, Chairman of CRF and Professor of Medicine at Columbia University Medical Center and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital.

Drs. Kirtane and Stone conducted two parallel meta-analyses examining DES vs. BMS use in both randomized, controlled trials and in observational registry analyses. The overall analysis represents the largest systematic overview of real-world (comprising both on-label and off-label) DES use to date and incorporates an updated overview of both the published literature as well as the most recent data from several unpublished studies presented in the last year.

The findings from these parallel studies are striking, said Dr. Stone.

The meta-analysis of 22 randomized trials included more than 9000 patients with recent follow-up from previously published trials. According to the results, DES resulted in small non-significant reductions in death and MI, with a greater than 50% decrease in subsequent TVR procedures, said Dr. Stone, adding that these findings are consistent with both on-label and off-label use of DES.

And in the 30-study registry meta-analysis (involving more than 170,000 real-world patients), DES resulted in significant 20% and 11% reductions in death and MI, respectively, with a similar reduction in TVR (47%) as in the randomized trials, even after adjustment for confounding variables, said Dr. Stone. These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year.

The findings were consistent and robust across a variety of study designs and even in trials incorporating longer-term follow-up; trials that were included were required to follow patients for at least one year.

Dr. Kirtane remarked that these findings should help to reassure patients and physicians about the safety of DES in off-label use.

Even with the stated limitations of registry data, the bottom line from both randomized trials and observational analyses is consistent: we can reduce the need for repeat procedures and we clearly are not harming patients with DES, he added.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. An invitation to Europes largest forum on breast cancer
2. Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification
3. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
4. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
5. Medco Breaks Ground For Worlds Largest Automated Pharmacy
6. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
7. AMSA Annual Convention: Largest Gathering of Medical Students Celebrates 58 Years of Student Activism
8. McGraw-Hill Professional Enters Partnership with American College of Physicians, the Worlds Largest Internal Medicine Organization
9. Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists
10. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
11. $30.3 Million Jury Verdict Believed to Be New Jerseys Largest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
Breaking Medicine Technology: